Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus-souche a/michigan/45/2015 (h1n1)-like: reassortanten virus nymc x-275), haemagglutininum influenzae a (h3n2) (virus-souche a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortanten virus ivr-186), haemagglutininum influenzae b (virus-souche b/colorado/06/2017-wie: reassortanten virus nymc bx-69a, abgeleitet von b/maryland/15/2016 (victoria-linie)) - suspension zur injektion in einer fertigspritze - haemagglutininum influenzae a (h1n1) (virus souche a/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus ivr-186) 15 µg, haemagglutininum influenzae b (virus souche b/colorado/06/2017-like: reassortant virus nymc bx-69a derived from b/maryland/15/2016 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013-like: reassortant virus wild type derived from b/phuket/3073/2013 (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - aktive immunisierung gegen influenza, ab dem 6. monat - impfstoffe

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus-souche a/michigan/45/2015 (h1n1)-like: reassortanten virus nymc x-275), haemagglutininum influenzae a (h3n2) (virus-souche a/hongkong/4801/2014 (h3n2)-like: reassortanten virus nymc x-263b), haemagglutininum influenzae b (virus-souche b/brisbane/60/2008) - injizierbare suspension - haemagglutininum influenzae a (h1n1) (virus-souche a/michigan/45/2015 (h1n1)-like: reassortanten virus nymc x-275) 15 µg, haemagglutininum influenzae a (h3n2) (virus-souche a/hongkong/4801/2014 (h3n2)-like: reassortanten virus nymc x-263b) 15 µg, haemagglutininum influenzae b (virus-souche b/brisbane/60/2008) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, der rest: formaldehydum max. 100 µg, octoxinolum-9 max. 500 µg, ovalbuminum max. 0,05 µg, kunststoff nein, neomycinum nichts, wasser zu iniectabilia q.s. zu der suspension 0,5 ml. - aktive immunisierung gegen influenza, ab dem 6. monat - impfstoffe

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus-souche a/michigan/45/2015 (h1n1)-like: reassortanten virus nymc x-275), haemagglutininum influenzae a (h3n2) (virus-souche a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortanten virus ivr-186), haemagglutininum influenzae b (virus-souche b/colorado/06/2017-wie: reassortanten virus nymc bx-69a, abgeleitet von b/maryland/15/2016) - injizierbare suspension - haemagglutininum influenzae a (h1n1) (virus souche a/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus ivr-186) 15 µg, haemagglutininum influenzae b (virus souche b/colorado/06/2017-like: reassortant virus nymc bx-69a derived from b/maryland/15/2016) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, residui: formaldehydum max. 30 µg, octoxinolum-9 max. 200 µg, neomycinum max. 7.5 pg, ovalbuminum max. 50 ng, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. - aktive immunisierung gegen influenza, ab dem 6. monat - impfstoffe

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275 derived from a/michigan/45/2015), haemagglutininum influenzae a (h3n2) (virus souche a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus ivr-186 derived from a/singapore/infimh-16-0019/2016 ), haemagglutininum influenzae b (virus souche b/colorado/06/2017-like: reassortant virus nymc bx-69a derived from b/maryland/15/2016 (victoria lineage)) - suspension injectable en seringue préremplie - haemagglutininum influenzae a (h1n1) (virus souche a/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275 derived from a/michigan/45/2015) 60 µg, haemagglutininum influenzae a (h3n2) (virus souche a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus ivr-186 derived from a/singapore/infimh-16-0019/2016 ) 60 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013 (yamagata lineage) (wild type)) 60 µg, haemagglutininum influenzae b (virus souche b/colorado/06/2017-like: reassortant virus nymc bx-69a derived from b/maryland/15/2016 (victoria lineage)) 60 µg, natrii chloridum, dinatrii phosphas, natrii dihydrogenophosphas anhydricus, octoxinolum-9, aqua ad iniectabile q.s. ad suspensionem pro 0.7 ml corresp. natrium 2.72 mg. - immunisation active contre l'influenza, dès 65 ans - impfstoffe

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (rha) (virus souche a/michigan/45/2015)-like: reassortant virus nymc x-275 derived from a/michigan/45/2015), haemagglutininum influenzae a (h3n2) (rha) (virus souche a/singapore/infimh-16-0019/2016)-like: reassortant virus ivr-186 derived form a/singapore/infimh-16-0019/2016), haemagglutininum influenzae b (rha) (virus souche b/phuket/3073/2013-like: reassortant virus b/phuket/3073/2013 (yamagata lineage)) - solution injectable dans une seringue pré-remplie - haemagglutininum influenzae a (h1n1) (adnr) (virus souche a/michigan/45/2015)-like: reassortant virus nymc x-275 derived from a/michigan/45/2015) 45 µg, haemagglutininum influenzae a (h3n2) (adnr) (virus souche a/singapore/infimh-16-0019/2016)-like: reassortant virus ivr-186 derived form a/singapore/infimh-16-0019/2016) 45 µg, haemagglutininum influenzae b (adnr) (virus souche b/phuket/3073/2013-like: reassortant virus b/phuket/3073/2013 (yamagata lineage)) 45 µg, haemagglutininum influenzae b (adnr) (virus souche b/colorado/6/2017-like: reassortant virus nymc bx-69a derived from b/maryland/15/2016 (victoria lineage)) 45 µg, natrii dihydrogenophosphas monohydricus, dinatrii phosphas dodecahydricus, natrii chloridum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 0.5 ml corresp. natrium 1.84 mg, residui: octoxinolum-9. - immunisation active contre l'influenza, dès 18 ans - impfstoffe

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortanten virus ivr-180, abgeleitet von a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2) (virus-stamm a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortanten virus-feder-104 ), haemagglutininum influenzae b (virus-stamm b/phuket/3073/2013 (yamagata-linie)) - injektionssuspension - haemagglutininum influenzae a (h1n1) (virus stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derived from a/singapore/gp1908/2015) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus nib-104 ) 15 µg, haemagglutininum influenzae b (virus stamm b/colorado/06/2017-like: reassortant virus b/maryland/15/2016 nymc bx-69a (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alfa-tocopheroli hydrogenosuccinas, residui: ovalbuminum max. 0.05 µg, formaldehydum max. 5 µg, natrii desoxycholas max. 65 µg, gentamicini sulfas nihil, hydrocortisonum nihil, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. - aktive immunisierung gegen influenza, ab 36 monaten - impfstoffe

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus-souche a/brisbane/02/2018 (h1n1)-pdm09: reassortanten virus ivr-190, abgeleitet von a/brisbane/02/2018), haemagglutininum influenzae a (h3n2) (virus-souche a/kansas/14/2007 (h3n2)-like: reassortanten virus nymc x-327, abgeleitet von a/kansas/14/2017), haemagglutininum influenzae b (virus-souche b/colorado/06/2017 (victoria-linie)-wie: reassortanten virus nymc bx-69a, abgeleitet von b/maryland/15/2016) - suspension zur injektion in einer fertigspritze - haemagglutininum influenzae a (h1n1) (virus-souche a/brisbane/02/2018 (h1n1)-pdm09: reassortanten virus ivr-190, abgeleitet von a/brisbane/02/2018) 15 µg, haemagglutininum influenzae a (h3n2) (virus-souche a/kansas/14/2007 (h3n2)-like: reassortanten virus nymc x-327, abgeleitet von a/kansas/14/2017) 15 µg, haemagglutininum influenzae b (virus-souche b/colorado/06/2017 (victoria-linie)-wie: reassortanten virus nymc bx-69a, abgeleitet von b/maryland/15/2016) 15 µg, haemagglutininum influenzae b (virus-souche b/phuket/3073/2013 (yamagata-linie)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, wasser ad iniectabilia q.s. zu der suspension mit 0,5 ml, der rest: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - aktive immunisierung gegen influenza, ab dem 6. monat - impfstoffe

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)-like: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus san-010 derived from a/darwin/9/2021), haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: derived from b/michigan/01/2021 (victoria lineage)(wild type)) - suspension injectable en seringue préremplie - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)-like: reassortant virus ivr-215 derived from a/victoria/2570/2019) 60 µg, haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus san-010 derived from a/darwin/9/2021) 60 µg, haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: derived from b/michigan/01/2021 (victoria lineage)(wild type)) 60 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013 (yamagata lineage) (wild type)) 60 µg, natrii chloridum, dinatrii phosphas, natrii dihydrogenophosphas anhydricus, octoxinolum-9, aqua ad iniectabile q.s. ad suspensionem pro 0.7 ml corresp. natrium 2.72 mg. - immunisation active contre l'influenza, dès 65 ans - impfstoffe

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus-stamm a/brisbane/02/2018 (h1n1)-like: reassortanten virus ivr-190, abgeleitet von a/brisbane/02/2018), haemagglutininum influenzae a (h3n2) (virus-stamm a/kansas/14/2017 (h3n2)-like: reassortanten virus nymc x-327, abgeleitet von a/kansas/14/0217), haemagglutininum influenzae b (virus-stamm b/colorado/06/2017-wie: reassortanten virus b/maryland/15/2016 nymc bx-69a (victoria-linie)) - injektionssuspension - haemagglutininum influenzae a (h1n1) (virus-stamm a/brisbane/02/2018 (h1n1)-like: reassortanten virus ivr-190, abgeleitet von a/brisbane/02/2018) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/kansas/14/2017 (h3n2)-like: reassortanten virus nymc x-327, abgeleitet von a/kansas/14/0217) 15 µg, haemagglutininum influenzae b (virus-stamm b/colorado/06/2017-wie: reassortanten virus (b/maryland/15/2016 nymc bx-69a (victoria-linie)) 15 µg, haemagglutininum influenzae b (virus-stamm b/phuket/3073/2013 (yamagata-linie)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesium, chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, der rest: ovalbuminum max. 0,05 µg, formaldehydum max. 5 µg, natrii desoxycholas max. 65 µg, gentamicini sulfas nichts, hydrocortisonum nichts, wasser zu iniectabilia q.s. zu der suspension 0,5 ml. - aktive immunisierung gegen influenza, ab 36 monaten - impfstoffe

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus stamm a/guangdong-maonan/swl1536/2019 (h1n1)-like: reassortant virus cnic-1909 derived from a/guangdong-maonan/swl1536/2019), haemagglutininum influenzae a (h3n2) (virus stamm a/hong kong/2671/2019 (h3n2)-like: reassortant virus nib-121 derived from a/hong kong/2671/2019), haemagglutininum influenzae b (virus stamm b/washington/02/2019-like: reassortant virus b/washington/02/2019 (victoria lineage)) - injektionssuspension - haemagglutininum influenzae a (h1n1) (virus stamm a/guangdong-maonan/swl1536/2019 (h1n1)-like: reassortant virus cnic-1909 derived from a/guangdong-maonan/swl1536/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/hong kong/2671/2019 (h3n2)-like: reassortant virus nib-121 derived from a/hong kong/2671/2019) 15 µg, haemagglutininum influenzae b (virus stamm b/washington/02/2019-like: reassortant virus b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum. - aktive immunisierung gegen influenza, ab 36 monaten - impfstoffe